Pancreastatin predicts survival in neuroendocrine tumors

Annals of Surgical Oncology

Volumn 21, Issue 9, 2014, Pages 2971-2980

  Sherman, Scott K ^a   Maxwell, Jessica E ^a   O'Dorisio, M Sue ^a   O'Dorisio, Thomas M ^a   Howe, James R ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; NEUROKININ A; PANCREASTATIN; SEROTONIN; PANCREAS HORMONE; PANCREASTATIN-52; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL STUDY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PREOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMALL BOWEL NEUROENDOCRINE TUMOR; TIME TO TREATMENT; TUMOR GROWTH; VERY ELDERLY; CANCER GRADING; CLINICAL TRIAL; INTESTINE TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR VOLUME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC HORMONES; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN; YOUNG ADULT;

EID: 84906263453     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3728-0     Document Type: Article

References (47)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.
2. Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120-34.
3. Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95:135-56.
4. Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140:891-7; (discussion 7-8).
5. Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741-51.
6. Taner T, Atwell TD, Zhang L, et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB (Oxford). 2013;15:190-5.
7. Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl. 7):vii124-30.
8. Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology. 2011;93:223-9.
9. Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg. 2012;99:1480-6.
10. Eriksson J, Stalberg P, Nilsson A, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg. 2008;32:930-8.
11. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129-36.
12. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-76.
13. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37. (Pubitemid 36759176)
14. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-63.
15. Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-16.
16. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-23.
17. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-13.
18. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282-9.
19. Turner GB, Johnston BT, McCance DR, et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. 2006;55:1586-91. (Pubitemid 44629208)
20. Nikou GC, Marinou K, Thomakos P, et al. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with nonfunctioning pancreatic endocrine tumours. Pancreatology. 2008;8:510-9.
21. Vinik AI, Silva MP, Woltering EA, Go VL, Warner R, Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38:876-89.
22. Jensen EH, Kvols L, McLoughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007;14:780-5. (Pubitemid 46175327)
23. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685-90. (Pubitemid 27372168)
24. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39:753-66.
25. O'Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 2010;39:611-6.
26. Ito T, Igarashi H, Jensen RT. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas. 2012;41:505-7.
27. Stronge RL, Turner GB, Johnston BT, et al. A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours. Ann Clin Biochem. 2008;45:560-6.
28. Rustagi S, Warner RR, Divino CM. Serum pancreastatin: the next predictive neuroendocrine tumor marker. J Surg Oncol. 2013;108:126-8.
29. Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11:264-71.
30. Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012;41:508-11.
31. Dahdaleh FS, Calva-Cerqueira D, Carr JC, et al. Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution. Ann Surg Oncol. 2012;19:966-72.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
33. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343-6. (Pubitemid 26342716)
34. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B. 1972;34:187-220.
35. Konecki DS, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem. 1987;262:17026-30. (Pubitemid 18017665)
36. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-49. (Pubitemid 36337325)
37. Sanchez-Margalet V, Gonzalez-Yanes C, Najib S, Santos-Alvarez J. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul Pept. 2010;161:8-14.
38. O'Connor DT, Cadman PE, Smiley C, et al. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab. 2005;90:5414-25. (Pubitemid 41262310)
39. Biswas N, Friese RS, Gayen JR, Bandyopadhyay G, Mahata SK, O'Connor DT. Discovery of a novel target for the dysglycemic chromogranin A fragment pancreastatin: interaction with the chaperone GRP78 to influence metabolism. PLoS One. 2014;9:e84132.
40. Sherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. Surgery. 2013;154:1206-14.
41. Sherman SK, Maxwell JE, Carr JC, et al. GIPR expression in gastric and duodenal neuroendocrine tumors. J Surg Res. 2014. doi:10.1016/j.jss.2014.01.044.
42. Carr JC, Sherman SK, Wang D, et al. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors. Ann Surg Oncol. 2013;20(Suppl. 3):739-46.
43. Waser B, Rehmann R, Sanchez C, Fourmy D, Reubi JC. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors. J Clin Endocrinol Metab. 2012;97:482-8.
44. Stivanello M, Berruti A, Torta M, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol. 2001;12(Suppl. 2):S73-7. (Pubitemid 33069691)
45. Kolby L, Bernhardt P, Sward C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept. 2004;120:269-73. (Pubitemid 38726216)
46. Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology. 2009;89:296-301.
47. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008;6:820-7.